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Introduction
Propofol is one of the most recent intravenous
anaesthetic agents being used in clinical practice. Propofol
has been used for induction and maintenance of anaesthesia,
for sedation to supplement regional anaesthesia as well as
sedation of patients in ICU.1
Propofol, when used for induction of anaesthesia in
shorter procedures, results in significantly quicker recovery
and earlier return of psychomotor function as compared to
thiopental and methohexital, irrespective of the agent used
for maintenance of anaesthesia.2
Induction with propofol has also some untoward
effects. These include pain on injection, myoclonus, apnea
and rarely thrombophlebitis.  However decrease in the
systemic blood pressure associated with induction of
anaesthesia with propofol is its most significant side effect.1
Direct myocardial depression and decreased
systemic vascular resistance have been implicated as
important factors in producing cardiovascular depression.
These effects are dose dependent. In addition to arterial
vasodilatation, propofol produces venodilation which
further contributes to its hypotensive effect.3 The smaller
increase in heart rate with propofol may account for the
larger decrease in arterial pressure than with an equipotent
dose of thiopental.4 Age enhances the cardio-depressant
response to propofol and dosage adjustments are required in
the elderly.5 In fact in some elective clinical scenarios, this
hypotensive effect of Propofol has been exploited to use it
as a drug of choice for controlled hypotensive technique.6
This hypotensive effect of propofol is not desirable mostly
and particularly in sick patients and older age group
patients.
A number of techniques have been tried to
counteract the hypotensive effects of propofol, for example
slow administration of drug, preloading, and administration
of vasoactive drugs to raise BP.1
Phenylephrine is a synthetic non-catecholamine that
stimulates principally alpha-1 adrenergic receptors by a
direct effect. Only a small part of the pharmacologic
response is due to its ability to release nor-epinephrine
(indirect acting) and it has a minimal effect on beta-
adrenergic receptors. 
Phenylephrine, 50 to 200 micrograms intravenous, is
often administered to adults to treat fall in blood pressure
that accompanies sympathetic nervous system blockade
produced by a regional anaesthetic technique and peripheral
vasodilatation that accompanies administration of injected
or inhaled anaesthetics.7
The objective of this study was to evaluate efficacy
of phenylephrine by mixing it in two different doses to
counteract the anticipated hypotensive effects of propofol
during induction of anaesthesia.   Hypotension is defined as
20% decrease in baseline systolic blood pressure recorded
before induction of anaesthesia.8
Original Article
Attenuation of Hypotension using Phenylephrine during induction of anaesthesia
with Propofol 
Muhammad Imran,  Fazal Hameed Khan, Mansoor Ahmed Khan
Department of Anaesthesia, Aga Khan University, Karachi.
Abstract
Objective: To observe if phenylephrine mixed with propofol can attenuate hypotensive effects of propofol during
induction of anaesthesia.
Methods: A total number of 135 adult ASA-I and ASA-II patients were divided into three groups.  (Group A, B
and C). All patients were induced with propofol 2.5 mg per kg. In Group A (control group) patients received
propofol mixed with 2cc of 0.9% normal saline.  Group B (study group) patients received propofol mixed with 2cc
of a solution containing phenylephrine 25µg/cc (total 50µg); Group C (study group) patients received propofol
mixed with 2cc of a solution containing phenylephrine 50µg/cc (total 100µg).  Haemodynamic variables like
systolic, diastolic, mean arterial blood pressure and heart rate were noted. Hypotension was defined as 20%
decrease in baseline systolic blood pressure recorded before induction of anaesthesia. 
Results: Phenylephrine in a dose of 100 micrograms attenuated the drop in systolic blood pressure. However
phenylephrine in a dose 50 micrograms did not effectively prevent anticipated drop in SBP. 
Conclusion: Phenylephrine in doses of 100 micrograms effectively attenuates anticipated hypotension upon
induction of general anaesthesia with propofol (JPMA 57:543:2007).
Vol. 57, No. 11, November 2007 543
We used LMA (Laryngeal mask airway) to maintain
the airway in our study as its cardiovascular response upon
insertion is not significant. Thus airway management was
less likely to impede in depicting the actual response of
drugs given for induction of anaesthesia.9
Patients and Methods
This randomized controlled trial was performed at
Aga Khan University Hospital after approval from Ethical
Review Committee. Written informed Consent was taken
from all the subjects. The study included 135 patients
divided into 3 groups randomly each consisting of 45
patients. Group A received propofol mixed with 2cc of 0.9%
normal saline .Group B were given propofol mixed with
50µg (2cc) of phenylephrine in concentration of 25µg/cc.
Group C received propofol mixed with 100µg (2cc) of
phenylephrine in a concentration of 50µg/cc .
Randomization was done with closed envelopes
technique.  Drug administration and data recording was
done by two separate persons blinded to the study group.
Inclusion criteria was ASA group I & II, patients aged
between 15-65 years and patients undergoing elective
surgery   requiring GA and LMA insertion. ASA group III &
IV, surgery requiring general anaesthesia with endotracheal
tube  insertion, patients with known cardiovascular disease
and hypersensitivity to propofol, failure to insert LMA in
first attempt, patients fasting  more then 10 hours, were
excluded from study. 
After arrival of the patient in OR, routine monitoring
was started including blood pressure, oxygen saturation,
ECG and end tidal CO2. Baseline reading of blood pressure,
heart rate and saturation were taken 5 minutes after the
application of monitors. Patients were pre-oxygenated   for
3 minutes using facemask at 4 L / min O2 with Lack circuit. 
Anaesthesia was then induced using Propofol
(mixed with study drug) given over 20 seconds.
Maintenance was with O2 \ N2O mixture and isoflurane 2%.
Ventilation was gently assisted using face mask and
maintaining ETCO2 between 30-40 mmHg. After proper
jaw relaxation LMA was inserted and connected to the
circuit. Patients who failed successful LMA insertion in first
attempt were excluded from the study. Breathing was gently
assisted until the restoration of spontaneous Breathing.
Systolic, diastolic, MAP, heart rate and SpO2 were
monitored from time zero (From start of induction) and then
at 1 minute interval until 6 minutes.    
Data was collected and analyzed using the software
Epi-data and SPSS version 10 for statistical analysis.
Demographic data was analyzed using Epi-data and
comparison of means was done. For haemodynamic
parameters SPSS was used and repeated measures ANOVA
was applied. Overall incidence of hypotension was
represented in terms of percentage and groups were
compared using the 'comparison of proportions'. P-value
was calculated and documented.
Results
The total numbers of patients studied were 135, with
45 in each group. Two patients in Group A and one in group
B were excluded from analysis as they became hypotensive
(Systolic blood pressure < 75mmHg) requiring intervention.
The mean age of the study group was 33.76 ± 9.75. There
were no statistically significant differences between the
groups with respect to age, weight and height (Table 1). 
Heart rate, systolic, diastolic, mean arterial pressure
and SpO2 were compared at 1 minute interval with baseline.
We compared mean values of group B and C   (Study group)
with group A (Control group) to note any significant
difference. Study groups (B & C) were also compared with
each other. 
Statistically significant difference from baseline
values was observed in mean systolic blood pressure at
minute 4 when group A was compared with group B (Table
2) , while this difference was statistically significant from
minute one to four when group A was compared with group
C (p < 0.05)  . Thus in group C systolic blood pressure did
not fall significantly for a longer period of time.  Similar
comparison was done for mean diastolic blood pressure and
no significant difference was found between group A and B.
Statistically significant difference was found at minute two
and three between group A and C. Mean arterial pressure
was also not significantly different between groups A and B
but the difference was statistically significant from minute 2
to 4 between groups A and C (p < 0.05) 
In contrast, change in heart rate was significant in
Group B and lasted for a longer period i.e. from minute one
to four as compared to that  in group C which was a slightly
shorter period from minute 1 to 3 (Table 2). Results depicted
a greater decrease in heart rate in group B (p < 0.05)
We also compared both study groups with each
Table 1. Comparison of demographic data between groups.
Control Group A
(n=43)
Study Group B
(n=44)
Study Group  C
(n=45)
Age (years)
Sex (Male/Female)
Height (cm) * 
Weight (kg) +
33.84 ± 10.11
21/22
161.43 ± 7.65
64.98 ± 10.70
32.39 ± 8.15
25/19
163.07 ± 5.31
65.25 ± 10.70
35.69 ± 10.51
24/21
159.76 ± 6.42
63.60 ± 10.51
Values are expressed as means ± Standard deviation
n =  Numbers
* Centimeters
+ Kilograms 
544 J Pak Med Assoc
other. Values for Systolic blood pressure were significantly
different between the two groups.  This difference was
found from minute 1 to 4 (p < 0.05) with better control of
systolic blood pressure in group C. The diastolic blood
pressure values had a significant difference from minute 1
to 6 (p < 0.05).  Mean arterial pressure was significantly
different from minute 1 to minute 5 (p < 0.05). The
difference in heart rate was significant only at minute 2 and
3.  Values of SpO2 were similar in all groups.
Hypotension was defined as 20% decrease in
systolic blood pressure from baseline value recorded before
induction of anaesthesia. The frequency of hypotension in
our study cases was 43% (59/135), with group A having
51%, group B 56 % (P < 0.8) and group C only 20% (P <
0.004). Hypotension in group A and B closely approximate
the values given in phase 4 study done by Hug et al on
25,000 patients8, which had a figure of 55.7% hypotension.
Mean drop in  SBP was 17.11% in group A , 20.16 % in
group B and 11.71 % in group C. Fall of systolic blood
pressure  (< 20 % from baseline) in Group A started at
minute 2, from minute 3 in group B which continued to 5
minutes (Control group). 
Rise in systolic blood pressure from baseline was
also analyzed. In group A, 13.9% (Total 6) patients, 9% in
Table 2. Comparison of Haemodynamics data of study groups ( B&C ) with control group A
Time Variables Group A Group B Group C P value group B P value group C
5 minute 
after
arrival
H.R*
SBP+
DBP++
MAP#
89.44± 12.26
130.60±15.33
81.84± 11.29
98.10±12.22
99.02±84.50
131.33±11.91
83.76±9.96
99.61±10.05
83.42 ±13.13
128.16±6.14
79.82±10.46
95.93±11.61
0.508
0.800
0.404
0.525
0.051
0.94
0.94
0.377
Before
induction
H.R
SBP
DBP
MAP
88.63±13.79
129.63±14.91
80.28±10.96
96.64±11.64
84.80±12.40
130.73±12.26
82.25±11.21
98.41±1078
83.36±12.97
125.0±15.71
78.22±9.66
93.81±10.95
0.183
0.64
0.410
0.465
0.068
0.185
0.352
0.243
Minute
1    
H.R
SBP
DBP
MAP
90.19±15.31
114.02±15.54
103.02±12.34
106.6±12.61
75.80±12.63
118.89±12.26
75.18±11.01
89.75±10.65
74.22±17.07
132.07±17.70
83.24±12.07
99.51±12.96
0.000
0.111
0.29
0.284
0.000
0.000
0.387
0.655
Minute
2
H.R
SBP
DBP
MAP
92.91±11.51
112.14±10.86
72.12±12.11
85.46±10.74
81.30±12.25
113.43±12.18
71.20±1099
85.28±10.68
72.71±16.61
125.07±18.11
78.07±11.76
93.73±13.30
0.000
0.603
0.714
0.939
0.000
0.000
0.02
0.02
Minute
3    
H.R
SBP
DBP
MAP
94.02±13.92
110.98±12.95
67.56±11.50
82.03±10.98
86.25±11.34
106.50±12.18
66.91±9.89
80.11±9.38
80.73±14.49
121.24±17.12
77.11±11.37
91.82±12.99
0.005
0.072
0.77
0.38
0.000
0.004
0.007
0.002
Minute
4    
H.R
SBP
DBP
MAP
93.93±13.71
110.35±11.72
67.19±11.12
81.57±11.24
88.02±8.51
105.35±9.26
65.30±10.38
78.57±9.49
88.24±13.42
116.69±17.12
71.58±11.34
86.61±12.57
0.018
0.023
0.437
0.181
0.053
0.047
0.083
0.050
Minute
5    
H.R
SBP
DBP
MAP
91.63±14.72
108.0±10.85
67.02±11.46
80.73±10.39
85.77±8.59
105.93±9.10
63.86±9.31
77.88±8.68
88.09±14.52
110.80±13.01
71.13±19.21
84.36±16.61
0.077
0.309
0.164
0.172
0.260
0.444
0.225
0.221
Minute
6    
H.R
SBP
DBP
MAP
88.81±12.37
107.53±9.19
64.66±10.39
78.95±9.65
88.14±12.32
107.82±9.10
63.68±6.35
78.39±6.38
90.45±13.92
110.40±10.81
68.40±9.71
82.40±9.53
8.44
0.908
0.697
0.811
0.600
0.231
0.115
0.128
* H.R   : Heart rate in  beats / minute                                Values expressed means  ± Standard  deviation 
+SBP : Systolic blood pressure in  millimeter of mercury.
++DBP : Diastolic blood pressure in  millimeter of mercury.
# MAP :  Mean  arterial pressure in  millimeter of mercury. 
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group B and 57.57 % in group C had increased systolic
blood pressure. Almost all occurred at 1 and 2 minute after
induction. Maximum rise in systolic pressure was 38.79%,
in group C, 16.5% in group A and 2.5% in group B. 
Discussion
Propofol`s direct myocardial depression and
reduction in systemic vascular resistance have been
implicated as important factors in producing cardiovascular
depression. In addition to arterial vasodilatation, propofol
produces venodilation due both to a reduction in
sympathetic activity  and a direct effect on the vascular
smooth muscle, which further contributes to its hypotensive
effect.10 Experiments in isolated myocardium suggest that
the negative inotropic effect of propofol results from a
decrease in intracellular calcium availability secondary to
inhibition of trans-sarcolemmal calcium influx.11 Propofol
alters the baroreflex mechanism, resulting in a relatively
smaller increase in heart rate for a given decrease in arterial
pressure.12 Study conducted by Clayes et al suggested that
the major haemodynamic effect of propofol is a decrease in
arterial pressure as a result of decrease SVR.13 This decline
in blood pressure may be more severe if patient is already
on vasodilator therapy such as a-1 blockers.14 Propofol has
been considered as one of the important predictors of
hypotension15 therefore vasoconstriction is indicated during
episodes of systemic hypotension, especially in cases where
it is stimulation or drug-induced vasodilatation as with
propofol .
A number of techniques have been tried to
counteract the hypotensive effects of propofol, for example
slow administration of the drug, preloading, and
administration of different drugs to elevate BP.16
Vasoconstrictors are useful adjuncts in the prevention and
treatment of ischaemia owing to their ability to increase
systemic blood pressure. In a study done by Ishiyama T et
al ephedrine was given just before induction to obtund the
hypotensive response of propofol induction.17
We used phenylepehrine with propofol to attenuate
its hypotensive effect during induction of anaesthesia. The
observation in our study suggests that addition of
phenylepehrine in a dose of 50 micrograms was insufficient
to completely obtund the hypotensive effects; however, the
dose of 100 micrograms was very effective. Phenylepehrine
in 100 micrograms dose  sustained systolic blood pressure
up to 4 minutes after induction which is the period of
maximum cardiovascular instability  caused by propofol.18
Cardiovascular effects of phenylepehrine are
mentioned mainly in prevention of spinal induced
hypotension and to preserve brain perfusion during carotid
endarterectomy. In obstetric patients phenylephrine
prevented spinal-induced hypotension decreases heart rate
and cardiac output while restoring systolic, mean, and
diastolic blood pressure.19 However these studies were
conducted in most obstetrical patients, who are young,
healthy with no cardiac issues.  In carotid endarterectomy, it
may induce segmental wall abnormalities detected by TEE.
However this occurs with indiscriminate use of this drug.
Administration of phenylephrine is claimed to improve
coronary perfusion pressure, although at the expense of
increasing after load and oxygen consumption. Our data
shows that the effect of phenylepehrine is more marked on
systolic then diastolic BP. Thus it may be better at
maintaining organ perfusion then coronary blood flow, but
in addition, concomitant venoconstricton increases venous
return and left ventricular preload. In most situations, the
increase in coronary perfusion pressure is more and it
offsets the effect of any increase in wall tension.20
The adverse effects of phenylepehrine on
cardiovascular systems are also well documented but most
of these effects were mentioned with its use as a topical
agent for example in ophthalmic preparations where very
potent solutions are used.21
Epicardial vessels, which possess mainly alpha-1
receptors, contribute only 5% to the total resistance of the
coronary circulation; therefore, alpha-1 agonists such as
phenylephrine have little influence on coronary resistance.22
Phenylephrine, like methoxamine, does not change cardiac
output in normal individuals but can cause a decrease in
cardiac output in patients with ischaemic heart disease.23
Stimulation of alpha-1 receptors in the heart by
phenylephrine may contribute to the production of cardiac
dysrhythmias during halothane anaesthesia.24 Therefore one
must be cautious in use of phenylepehrine especially in high
doses in coronary artery disease patients. We used
moderately low doses in our study then the usually
recommended doses of phenylephrine for the treatment of
hypotension.
In our study 57 % patients in group C had rise in
SBP from baseline. Maximum increase was 38% from
baseline. Most of patients had increase in SBP at 1st and
2nd minute with greatest increase in 2nd minute. However
pressure returned to baseline later on. This finding needs
consideration and exercise caution in patients who are
unpremedicated, anxious, given inadequate induction doses
and inadequately treated hypertensive patients. 
It has been mentioned that propofol increases the
risk of bradycardia, asystole, and death, qualitative and
quantitative analyses of data suggest that the risk of
bradycardia-related death during propofol anaesthesia is 1.4
per 100,000.25 This might increase the risk of potentiating
reflex bradycardia and attenuation of hypotension with use
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of phenylephrine. However in our study the maximum drop
in heart rate was 50% from baseline and minimum heart rate
was 45/minute. This finding was observed in group C. In
group B maximum drop was 38% from baseline.  Minimum
heart rate in this group was 52/minute. The decrease in heart
rate was not accompanied by decrease in blood pressure.
Phenylephrine induced bradycardia can be blocked by
atropine. Use of phenylephrine  should be avoided in
patients where cardiac output is maintained on elevated
heart rate and an optimum peripheral vascular resistance for
example aortic regurgitation and aortic stenosis. 
Overall incidence of hypotension was slightly more
in group B when compared with group A i.e. 56% vs. 51%
but episodes of hypotension were less in first 2 minutes in
group B as compared to A (12 vs.19), thereafter number of
patients getting hypotensive surpasses as in group A. This
could be due to the fact that a small dose of phenylephrine
prevented hypotension initially but this small dose was
consumed rapidly after which  hypotensive effects of
propofol predominated. However the incidence is not
statistically significant.
Conclusion
The observations of the presented study period the
effectiveness of phenylephrine in attenuation of anticipated
hypotension upon anaesthesia induction with propofol. We
found that phenylephrine in a dose of 100 microgram is
more effective then 50 microgram to prevent hypotension
with propofol induction.
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